0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Comparative Effectiveness of HIV Testing and Treatment in Highly Endemic Regions FREE

Eran Bendavid, MD, MS; Margaret L. Brandeau, PhD; Robin Wood, MD; Douglas K. Owens, MD, MS
[+] Author Affiliations

Author Affiliations: Division of General Internal Medicine (Dr Bendavid), Center for Health Policy and the Center for Primary Care and Outcomes Research (Drs Bendavid and Owens), and Department of Management Science and Engineering (Dr Brandeau), Stanford University, Stanford, California; Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa (Dr Wood); and Veterans Affairs Palo Alto Health Care System, Palo Alto, California (Dr Owens).


Arch Intern Med. 2010;170(15):1347-1354. doi:10.1001/archinternmed.2010.249.
Text Size: A A A
Published online

Background  Universal testing and treatment holds promise for reducing the burden of human immunodeficiency virus (HIV) in sub-Saharan Africa, but linkage from testing to treatment sites and retention in care are inadequate.

Methods  We developed a simulation of the HIV epidemic and HIV disease progression in South Africa to compare the outcomes of the present HIV treatment campaign (status quo) with 4 HIV testing and treating strategies that increase access to antiretroviral therapy: (1) universal testing and treatment without changes in linkage to care and loss to follow-up; (2) universal testing and treatment with improved linkage to care; (3) universal testing and treatment with reduced loss to follow-up; and (4) comprehensive HIV care with universal testing and treatment, improved linkage to care, and reduced loss to follow-up. The main outcome measures were survival benefits, new HIV infections, and HIV prevalence.

Results  Compared with the status quo strategy, universal testing and treatment (1) was associated with a mean (95% uncertainty bounds) life expectancy gain of 12.0 months (11.3-12.2 months), and 35.3% (32.7%-37.5%) fewer HIV infections over a 10-year time horizon. Improved linkage to care (2), prevention of loss to follow-up (3), and comprehensive HIV care (4) provided substantial additional benefits: life expectancy gains compared with the status quo strategy were 16.1, 18.6, and 22.2 months, and new infections were 55.5%, 51.4%, and 73.2% lower, respectively. In sensitivity analysis, comprehensive HIV care reduced new infections by 69.7% to 76.7% under a broad set of assumptions.

Conclusions  Universal testing and treatment with current levels of linkage to care and loss to follow-up could substantially reduce the HIV death toll and new HIV infections. However, increasing linkage to care and preventing loss to follow-up provides nearly twice the benefits of universal testing and treatment alone.

Figures in this Article

The human immunodeficiency virus (HIV) epidemic in many sub-Saharan African countries has stabilized in the past few years, with a few countries reporting reductions in incidence, prevalence, and mortality.13 However, the epidemic is still an unsustainable and disproportionate challenge to southern Africa, responsible for more than20% of adult mortality in some countries, an increasing number of orphans, and possible reversals in economic growth.1,4 Reducing the burden of the epidemic is a major goal of HIV testing and treatment programs, but difficulties in linking infected individuals to treatment sites and retaining them in care, low testing rates, and resource constraints challenge the capacity to achieve universal access.59

Recent studies suggest that universal testing and treatment may decrease HIV prevalence in highly endemic regions through reduced incidence (infected patients who receive treatment are less likely to infect others), while at the same time markedly reducing HIV mortality.10 This strategy has considerable appeal, and clinical trials looking at the effectiveness of early antiretroviral therapy (ART) for HIV prevention are currently under way.11 However, previous estimates of the benefits of universal testing and treatment did not take into account the poor linkage between testing and treatment sites and the high rates of attrition from care after treatment initiation. Among patients who receive a diagnosis of HIV infection in South Africa, one-third to two-thirds never return for follow-up care.12,13 In addition, many clinics report high rates of loss to follow-up (LTFU)—4% to 39% in a recent systematic review (after accounting for mortality following ART initiation).14 These factors are increasingly recognized as central barriers to scale-up of ART programs in sub-Saharan Africa.

Given the limited resources for scaling up HIV testing and treatment in Africa, assessing the role of improving linkage to care and reducing loss to follow-up is critical. In this study, we assess the epidemiologic and health effects of 4 strategies to increase access to antiretroviral therapy: universal testing and treatment without substantial changes in rates of linkage to care and LTFU; universal testing and treatment with improved linkage to care; universal testing and treatment with reduced LTFU; and comprehensive HIV care with universal testing and treatment, improved linkage to care, and reduced LTFU.

We developed a stochastic HIV disease and transmission model in an adult population similar to that in South Africa, where HIV transmission is predominantly heterosexual. We used the model to evaluate the relative effectiveness of different strategies for scaling up access to ART through expanded testing, improved linkage to care, earlier treatment initiation, and reduced rates of loss to follow-up. The model follows groups of uninfected and HIV-infected individuals over time, and aggregates individual health outcomes as well as epidemiologic measures of HIV burden, such as incidence and prevalence.

We designed the model to reflect the current pace of scale-up in South Africa, including the rate of HIV testing, rate of linkage to care, treatment initiation thresholds, and rates of loss to follow-up. We describe the model structure, key assumptions, and the scale-up strategies.

MODEL STRUCTURE

The model follows groups of 10 000 individuals representative of the population of South Africa by age, sex, HIV status, circumcision status, and number of sexual partners.1518 Individuals enter the population at age 15 years and leave the population when they die from HIV or other causes. Baseline demographic parameters are shown in Table 1. The population is followed in 1-month intervals over a period of 10 years, and the health status of individuals is evaluated monthly based on their age, sex, HIV status, and HIV testing and treatment history. Risk factors for infection and disease progression are presented in Table 1 and a supplement (available at the authors’ Web site, http://healthpolicy.stanford.edu/publications/comparative_effectiveness_of_hiv_testing_and_treatment_strategies_in_highly_endemic_regions/ and on request).

Table Graphic Jump LocationTable 1. Parameter Estimates and Data Sources
HIV INFECTION

Human immunodeficiency virus status in the initial time period of the model is determined by current estimates of age- and sex-specific HIV prevalence in South Africa. Individuals who are uninfected may become infected if they have at least 1 HIV-infected sexual partner. The number of sexual partnerships at any point in time is determined by estimates of concurrency in South Africa.20,38 The risk of infection per month is calculated based on the sex of the individual, the number of infected partners, and the viral load of any infected partners. The viral load of infected partners may be either suppressed or elevated, based on the distribution of viral loads in the population. Uninfected partners of individuals who recently seroconverted have a much higher risk of acquiring HIV infection. Risk of infection is reduced for men who are circumcised and for individuals who received HIV counseling. The magnitude of risk reduction is shown in Table 1.

HIV TESTING AND TREATMENT

Infected individuals are identified through HIV testing or when they develop a severe opportunistic disease. Individuals who develop a severe opportunistic disease are linked to care and initiate treatment, even if they were lost to care between testing and treatment or lost to follow-up. We assumed that those who are identified through testing are referred to an HIV treatment facility, where they are followed prior to and after starting ART. The imperfect linkage between testing and treatment sites, the treatment initiation criteria, and the LTFU after treatment initiation are shown in Table 2. We assumed that individuals were monitored on average every 6 months for clinical symptoms of disease progression and with CD4 lymphocyte counts.

Table Graphic Jump LocationTable 2. HIV Testing and Treatment Strategies

All individuals in our population are eligible to be tested. In the status quo strategy, testing rates reflect the current mix of voluntary testing and counseling or health care provider–initiated testing, while the universal testing and treatment strategies assume that 90% of the population is tested and that individuals undergo testing every 2 years on average. In the status quo strategy, we assumed that 67% of individuals who tested positive for HIV are linked with an HIV treatment facility.39 Without targeting linkage, we assume that this rate of presentation to treatment sites remains unchanged.

We used our previous work to model the progress of infected individuals.40,41 Individuals who are linked to a treatment program are monitored regularly to determine the appropriate timing for initiating ART. We assumed that individuals are monitored for clinical signs of advanced disease and CD4 lymphocyte counts to guide timing of treatment initiation. Timing of treatment initiation is a topic of substantial debate42; our status quo strategy estimates reflect current guidelines (Table 2). Finally, we tracked whether individuals remained in treatment over time. We estimated rates of LTFU based on clinical experience from Cape Town but considered the range of reported experience in southern Africa. Base-case estimates of each component of HIV care are shown in Table 2.

STRATEGIES FOR HIV CARE SCALE-UP

We projected the course of the epidemic using the status quo strategy and 4 additional strategies of universal testing and treatment. The strategies (Table 2) are as follows:

  • Status quo strategy: The number of people tested for HIV, accessing treatment centers, and starting treatment continues to increase, but the pace of scale-up remains similar to that observed since 2007.

  • Universal testing and treatment: In this strategy, there is a shift from the current rate of testing, in which 18% of the adult population have been tested previously and about 10% of the adult population are tested per year, to a strategy in which 90% of the adult population are tested in the first 2 years, and individuals seek an additional HIV test every 2 years on average. About 67% of those who have positive HIV test results are linked to a treatment facility and start treatment with first-line ART within 6 months after their diagnosis; and about 20% of individuals who start treatment are lost to follow-up in the first year of treatment. Compared with the status quo strategy, this strategy illustrates the benefits of universal testing and treatment with the current approaches to patient linkage and retention in care.

  • Universal testing and treatment with improved linkage to care: This is the same as strategy 2, except that linkage to care is now 100%; that is, every individual who has a positive HIV test result is linked with a treatment facility and starts treatment within 6 months of diagnosis. Rates of LTFU are unchanged.

  • Universal testing and treatment with prevention of LTFU: This is the same as strategy 2, except that retention in care is 100%. As with strategy 2, 33% of individuals with positive HIV test results are not linked with treatment facilities.

  • Universal testing, improved linkage to care, early treatment, and prevention of LTFU (comprehensive): This includes universal testing, improved linkage to care, early treatment, and prevention of LTFU as noted for strategies 2 to 4. While perfect linkage and retention in care are not likely to be possible, this strategy is illustrative of the maximal benefits of a universal testing and treatment approach.

OUTCOMES MEASURED

We measured 2 primary outcomes: gains in life expectancy and reduction in new HIV infections at the end of 10 years compared with the status quo strategy. The former is a measure of health benefits for individuals, whereas the latter is an important determinant of the burden of disease. While the benefits of scaling up HIV care apply most directly to the infected population, the benefits spill over to the uninfected population through reduced HIV transmission. Thus, we measured the gains in life expectancy across the entire population. We estimated 4 other important epidemiologic and health outcomes: reduction in HIV-related deaths, HIV death rates, adult HIV prevalence, and population growth. Life expectancy gains are reported using a 3% discount rate.

SENSITIVITY ANALYSIS

Recognizing the challenges in achieving 100% linkage and retention in care, we varied the rates from the status quo levels to perfect linkage and retention and report the results in percentage of improvement over universal testing and treatment without changes to linkage or retention in care. For example, improving linkage from 67% to 90% may provide a 25% greater improvement in life expectancy compared with universal testing and treatment without improvements in linkage. In probabilistic sensitivity analysis we varied all parameters simultaneously (detailed in the supplement). We drew each input parameter from a random distribution (normal, beta, gamma, or uniform) and repeated the analysis 1000 times. We report the results of this analysis as a 95% uncertainty bound around our estimates. These bounds are reported throughout the “Results” section and in the Tables and Figures.

In the status quo strategy, we estimate that the prevalence of HIV in South African adults will decrease from 18.0% to 17.2% over the next decade. This is consistent with current epidemiologic projections and recent trends.43 We estimate the HIV-specific mortality rate in the first year of our analysis to be 1140 deaths per 100 000 individuals older than 15 years, consistent with World Health Organization estimates from vital registration data and demographic projections.22,44

MORTALITY BENEFITS OF TESTING AND TREATMENT STRATEGIES

Compared with the status quo strategy, universal testing and treatment alone (strategy 2) was associated with a per-person gain in life expectancy of 12.0 (11.3-12.2) months averaged over the entire population. Universal testing and treatment with improved linkage to care (strategy 3) and prevention of LTFU (strategy 4) were associated with greater life expectancy gains: 16.1 and 18.6 months per person over the entire population, respectively, while comprehensive HIV care (strategy 5) was associated with an average life expectancy gain of 22.2 months per person. Two related events account for the gains in life-years: a decrease in HIV mortality from improved case detection and care, and an increase in the size of the population owing to the decreased mortality in the population of childbearing age. At the end of 10 years, we estimate that the comprehensive strategy resulted in 61.6% fewer deaths from HIV compared with the status quo strategy and an HIV death rate of 415 (318-515) per 100 000 person-years, 63.5% lower than the status quo strategy. Universal testing and treatment alone (strategy 2) yielded a 27.7% decrease in deaths from HIV and an HIV mortality rate of 802 (664-948) per 100 000 person-years. The mortality benefits are summarized in Table 3 and Figure 1.

Place holder to copy figure label and caption
Figure 1.

Estimated deaths from human immunodeficiency virus (HIV) over 10 years in South Africa for different HIV testing and treatment strategies. A comparison of the total number of HIV-related deaths over 10 years, by strategy, scaled to South Africa. The error bars represent the 95% confidence bounds from the probabilistic sensitivity analysis. LTFU indicates loss to follow-up.

Graphic Jump Location
Table Graphic Jump LocationTable 3. Mortality Benefits of HIV Testing and Treatment Strategies
TRANSMISSION BENEFITS OF TESTING AND TREATMENT STRATEGIES

While scaling up HIV care is likely to improve survival of HIV-infected individuals, the effect on HIV transmission and prevalence is less obvious. Increasing treatment coverage may reduce infectivity per coital act. However, the longer survival of HIV-infected individuals and reduction in deaths may increase the opportunity for individuals to infect others and may increase prevalence, which is in turn a determinant of infection. We estimate the number of new infections in the adult South African population over the next 10 years to be 4.5 (3.8-5.1) million in the status quo strategy, and 1.2 (0.9-1.6) million in a comprehensive strategy, a 73.2% reduction.

The decrease in new infections led to reductions in adult HIV prevalence compared with the status quo strategy of 1.6%, 2.5%, 1.9%, and 3.4% with universal testing and treatment alone, universal testing and treatment with improved linkage, universal testing and treatment with reduced LTFU, and the comprehensive strategy, respectively, at the end of 10 years. The reduction in new infections and HIV deaths, especially among individuals of childbearing age, was associated with an increase in the size of the population. We estimated 11.5% population growth over 10 years in the status quo strategy (about 1.1% per year), and 15.2% with universal testing and treatment alone (strategy 2). Figure 2 and Table 4 show the transmission and demographic benefits.

Place holder to copy figure label and caption
Figure 2.

Projected human immunodeficiency virus (HIV) prevalence in South Africa for different HIV testing and treatment strategies. LTFU indicates loss to follow-up.

Graphic Jump Location
Table Graphic Jump LocationTable 4. Transmission and Epidemiologic Benefits of HIV Testing and Treatment Strategiesa
SENSITIVITY ANALYSES

Figure 3 shows the sensitivity of our results to gradually improving linkage to care and reducing LTFU. The figure shows that even relatively modest improvements in linkage to care and prevention of LTFU provide substantial mortality and prevention benefits. A 10% higher linkage and 6% reduction in LTFU (67%-77% and 20%-14%, respectively) are associated with life expectancy improvements that are 30% higher than with universal testing and treatment alone. Similar improvements in linkage and prevention of LTFU are associated with 36% fewer HIV infections compared with universal testing and treatment alone. We performed 2-way sensitivity analysis on rates of testing and treatment initiation threshold, which showed that as long as treatment is initiated early, substantial reductions in prevalence and new infections can be accomplished with testing rates as low as 30% to 40% of the population. These results are discussed in the supplement.

Place holder to copy figure label and caption
Figure 3.

Sensitivity analysis of the mortality benefits and reduction in transmission from gradual improvements in linkage to care and prevention of loss to follow-up (LTFU). A, The mortality benefits; B, the reduction in new human immunodeficiency virus (HIV) infections. Each line represents the benefit compared with universal testing and treatment alone. The relative benefits for improved linkage range over 67% to 100% linkage, and for LTFU from 20% to 0% loss. The comprehensive strategy represents simultaneous improvements in linkage and prevention of LTFU. For example, universal testing and treatment with improved linkage to 80% results in a gain of about 2.5 months of life expectancy, or 15% improvement, over universal testing and treatment alone.

Graphic Jump Location

Our comparative evaluation of the mortality and transmission benefits of scaling up HIV testing and treatment in sub-Saharan Africa provides several important insights. First, universal testing and early treatment alone have important health and epidemiologic benefits, but we estimate that they provide about half of the benefits of a comprehensive scale-up strategy that also includes improved linkage to care and prevention of loss to follow-up. Second, the mortality and transmission benefits of scaling up HIV testing and treatment have implications for population growth. Finally, we estimate that even under a strategy of comprehensive HIV care it will take longer than a decade to substantially reduce the burden of South Africa's widespread epidemic.

Our results support the notion that universal testing and treatment have significant mortality benefits in South Africa. Recent estimates from South Africa suggest that ART may prolong life expectancy of infected individuals by 12.5 years.45 We estimate that a comprehensive HIV testing, treatment, and care strategy will increase the average life expectancy of the entire population by 22 months compared with the status quo strategy. From 1990 to 2006, life expectancy in South Africa declined by about 12 years. Scaling up HIV testing and treatment may go a considerable way toward reversing that trend.19 Although a comprehensive plan with perfect linkage and full retention in care is not realistic, it provides an important bound for the possible benefits.

However, over a decade, the benefits of universal testing and treatment alone are much lower than the benefits of universal testing and treatment with improved linkage to care and prevention of loss to follow-up. This underscores the role of increasing the number of people who initiate treatment early: each individual who starts treatment early decreases the number of downstream infections by more than 1. Insights from mathematical epidemiology suggest that, in the absence of ART, each individual infected with HIV transmits the infection to more than 1 person, on average, over his or her lifetime. Thus, the benefits of long-term effective ART are multiplied, and so are the losses from having individuals forego ART because of poor linkage to care or LTFU.

Despite all these benefits, we find that even under the comprehensive strategy of HIV care, the burden of disease over the next decade is expected to remain substantial. Some researchers suggest that it would take as long as 50 years to reduce HIV prevalence in South Africa to below 1%.10 Our estimates, which include a detailed microsimulation of HIV disease and treatment, demographic changes, and multiple transmission risk factors, agree with these estimates: we show a nearly linear decrease in prevalence of 4.2% over a decade, suggesting that it would take more than 4 decades at the estimated rate of decline to decrease prevalence to around 1%.

Our estimates of benefits rely on several important assumptions. Most important, we assumed that HIV transmission risk is reduced for individuals receiving ART. Although much evidence supports this phenomenon, to our knowledge it has not been verified in a major clinical trial to date.46,47 We made several assumptions about the benefits of treatment in South Africa that affect our estimates of the longevity benefits of ART but do not change the comparative effectiveness of the strategies we examined. We also assumed no behavioral risk modification with decreasing disease burden; for example, as HIV mortality and prevalence drop, individuals may perceive the disease as less threatening and increase risk behaviors, such as multiple concurrent partnerships.48 However, we had no basis for assuming the type or extent of behavior risk modification. Finally, we assumed that the fertility rate will remain stable (ie, the number of children per woman will not change over the next decade). A decrease in the fertility rate may slow the decline in prevalence, because the growth in population size will slow down while the number of infected individuals may not change appreciably.

Our analysis uses a detailed epidemiologic simulation model to estimate the mortality and transmission benefits of HIV testing, treatment, and care in South Africa and quantifies the comparative effectiveness of alternative strategies for universal testing and treatment. We find that scaling up all aspects of HIV care nearly doubles the benefits of universal testing and treatment alone. An economic and operational evaluation of these strategies would further help in clarifying priorities.

Correspondence: Eran Bendavid, MD, MS, Division of General Internal Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305-8526 (ebd@stanford.edu).

Accepted for Publication: February 10, 2010.

Author Contributions:Study concept and design: Bendavid, Wood, and Owens. Acquisition of data: Bendavid. Analysis and interpretation of data: Brandeau and Owens. Drafting of the manuscript: Bendavid and Owens. Critical revision of the manuscript for important intellectual content: Brandeau and Wood. Statistical analysis: Bendavid and Owens. Obtained funding: Owens. Study supervision: Brandeau, Wood, and Owens. Modeling expertise: Brandeau.

Financial Disclosure: None reported.

Funding/Support: This research is supported in part by the National Institute of Allergy and Infectious Diseases (K01-AI084582), the Department of Veterans Affairs, and the National Institute on Drug Abuse (R01 DA15612).

Role of the Sponsors: The funding agencies had no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

UNAIDS, Report on the Global AIDS Epidemic.  Geneva, Switzerland Joint United Nations Programme on HIV/AIDS2008;
UNAIDS, AIDS Epidemic Update.  Geneva, Switzerland Joint United Nations Programme on HIV/AIDS2007;
Gregson  SGarnett  GPNyamukapa  CA  et al.  HIV decline associated with behavior change in eastern Zimbabwe. Science 2006;311 (5761) 664- 666
PubMed Link to Article
Dixon  S McDonald  SRoberts  J The impact of HIV and AIDS on Africa's economic development. BMJ 2002;324 (7331) 232- 234
PubMed Link to Article
UNAIDS/World Health Organization, Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report.  Geneva, Switzerland UNAIDS/World Health Organization2009;
UNAIDS, Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support.  Geneva, Switzerland UNAIDS2007;
UNAIDS/World Health Organization, Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities.  Geneva, Switzerland UNAIDS/World Health Organization2007;
Stringer  JSZulu  ILevy  J  et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296 (7) 782- 793
PubMed Link to Article
Brinkhof  MPujades-Rodriguez  MEgger  M Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009;4 (6) e5790
PubMed Link to Article
Granich  RMGilks  CDye  CDe Cock  KWilliams  B Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373 (9657) 48- 57
PubMed Link to Article
 A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. HIV Prevention Trials Web site. http://www.hptn.org/research_studies/HPTN052.asp. Accessed June 12, 2009
Bassett  IVGiddy  JWang  B  et al.  Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med 2008;9 (10) 863- 867
PubMed
Bassett  IRegan  SChetty  S  et al.  Who starts ART in Durban, South Africa? not everyone who should [abstract WEAD102]. Conference of International AIDS Society July 19-22, 2009 Cape Town, South Africa
Rosen  SFox  MPGill  CJ Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4 (10) e298
PubMed Link to Article
 US Census Bureau International Data Base. US Census Bureau Web site. http://www.census.gov/ipc/www/idb/tables.html. Accessed July 15, 2009
Shisana  ORehle  TSimbayi  L  et al.  South African National HIV Prevalence, Incidence, Behaviour and Communication Survey: A Turning Tide Among Teenagers?  Cape Town, South Africa HSRC Press2008;
Parker  WMakhubele  BNtlabati  PConnolly  C Concurrent Sexual Partnerships Amongst Young Adults in South Africa: Challenges for HIV Prevention Communication.  Johannesburg, South Africa CADRE2007;
Williams  BGLloyd-Smith  JOGouws  E  et al.  The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med 2006;3 (7) e262
PubMed Link to Article
 World Health Organization life tables for WHO member states. World Health Organization Web site. http://www.who.int/whosis/database/life_tables/life_tables.cfm. Accessed July 15, 2009,
 Demographic and Health Survey, ORC Macro. http://www.measuredhs.com. Accessed May 1, 2010
Connolly  CSimbayi  LShanmugam  RNqeketo  A Male circumcision and its relationship to HIV infection in South Africa: results from a national survey in 2002. S Afr Med J 2009;98 (10) 789- 794
PubMed
Dorrington  RJohnson  LBradshaw  DDaniel  T The Demographic Impact of HIV/AIDS in South Africa: National and Provincial Indicators for 2006.  Cape Town, South Africa Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa2006;
Wawer  MJGray  RHSewankambo  NK  et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191 (9) 1403- 1409
PubMed Link to Article
Gray  RHWawer  MJBrookmeyer  R  et al. Rakai Project Team, Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357 (9263) 1149- 1153
PubMed Link to Article
Quinn  TCWawer  MJSewankambo  N  et al. Rakai Project Study Group, Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342 (13) 921- 929
PubMed Link to Article
Auvert  BTaljaard  DLagarde  ESobngwi-Tambekou  JSitta  RPuren  A Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2 (11) e298
PubMed Link to Article
Bailey  RCMoses  SParker  CB  et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369 (9562) 643- 656
PubMed Link to Article
Gray  RHKigozi  GSerwadda  D  et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369 (9562) 657- 666
PubMed Link to Article
Kamb  MLFishbein  MDouglas  JM  Jr  et al. Project RESPECT Study Group, Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280 (13) 1161- 1167
PubMed Link to Article
Williams  BGKorenromp  EGouws  ESchmid  GAuvert  BDye  C HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis 2006;194 (10) 1450- 1458
PubMed Link to Article
Auvert  BMales  SPuren  ATaljaard  DCaraël  MWilliams  B Can highly active antiretroviral therapy reduce the spread of HIV? a study in a township of South Africa. J Acquir Immune Defic Syndr 2004;36 (1) 613- 621
PubMed Link to Article
Badri  MLawn  SDWood  R Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008;889
PubMed Link to Article
Badri  MCleary  SMaartens  G  et al.  When to initiate highly active antiretroviral therapy in sub-Saharan Africa? a South African cost-effectiveness study. Antivir Ther 2006;11 (1) 63- 72
PubMed
Orrell  CHarling  GLawn  SD  et al.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007;12 (1) 83- 88
PubMed
Holmes  CBWood  RBadri  M  et al.  CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42 (4) 464- 469
PubMed Link to Article
Badri  MLawn  SDWood  R Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006;368 (9543) 1254- 1259
PubMed Link to Article
Lawn  SDLittle  FBekker  L  et al.  Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009;23 (3) 335- 342
PubMed Link to Article
Pettifor  AERees  HVKleinschmidt  I  et al.  Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005;19 (14) 1525- 1534
PubMed Link to Article
April  MWalensky  RChang  Y  et al.  Trends in HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies.  Conference on Retroviruses and Opportunistic Infections February 8-11, 2009 Montreal, Quebec, Canada
Bendavid  EYoung  SDKatzenstein  DABayoumi  AMSanders  GMOwens  DK Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a Southern African analysis. Arch Intern Med 2008;168 (17) 1910- 1918
PubMed Link to Article
Bendavid  EWood  RKatzenstein  DABayoumi  AMOwens  DK Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr 2009;52 (1) 106- 113
PubMed Link to Article
De Cock  KM Plenary talk.  HIV Implementers' Meeting June 10, 2009 Windhoek, Namibia
 2008 Report on the global AIDS epidemic: epidemiology information. Joint United Nations Programme on AIDS Web site. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed November 2008
 WHO Mortality Database. http://www.who.int/healthinfo/morttables/en/. Accessed June 29, 2009
Walensky  RWolf  LWood  R  et al.  When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151 (3) 157- 166
PubMed Link to Article
Vernazza  PHirschel  BBernasconi  EFlepp  M HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Bulletin des Médecins Suisses 2008;89 (5) 165- 169
Reynolds  SMakumbi  FKagaayi  J  et al.  ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda.  Presented at: Conference on Retroviruses and Opportunistic Infections February 8-11, 2009 Montreal, Quebec, Canada
Cassell  MMHalperin  DTShelton  JDStanton  D Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006;332 (7541) 605- 607
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Estimated deaths from human immunodeficiency virus (HIV) over 10 years in South Africa for different HIV testing and treatment strategies. A comparison of the total number of HIV-related deaths over 10 years, by strategy, scaled to South Africa. The error bars represent the 95% confidence bounds from the probabilistic sensitivity analysis. LTFU indicates loss to follow-up.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Projected human immunodeficiency virus (HIV) prevalence in South Africa for different HIV testing and treatment strategies. LTFU indicates loss to follow-up.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Sensitivity analysis of the mortality benefits and reduction in transmission from gradual improvements in linkage to care and prevention of loss to follow-up (LTFU). A, The mortality benefits; B, the reduction in new human immunodeficiency virus (HIV) infections. Each line represents the benefit compared with universal testing and treatment alone. The relative benefits for improved linkage range over 67% to 100% linkage, and for LTFU from 20% to 0% loss. The comprehensive strategy represents simultaneous improvements in linkage and prevention of LTFU. For example, universal testing and treatment with improved linkage to 80% results in a gain of about 2.5 months of life expectancy, or 15% improvement, over universal testing and treatment alone.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Parameter Estimates and Data Sources
Table Graphic Jump LocationTable 2. HIV Testing and Treatment Strategies
Table Graphic Jump LocationTable 3. Mortality Benefits of HIV Testing and Treatment Strategies
Table Graphic Jump LocationTable 4. Transmission and Epidemiologic Benefits of HIV Testing and Treatment Strategiesa

References

UNAIDS, Report on the Global AIDS Epidemic.  Geneva, Switzerland Joint United Nations Programme on HIV/AIDS2008;
UNAIDS, AIDS Epidemic Update.  Geneva, Switzerland Joint United Nations Programme on HIV/AIDS2007;
Gregson  SGarnett  GPNyamukapa  CA  et al.  HIV decline associated with behavior change in eastern Zimbabwe. Science 2006;311 (5761) 664- 666
PubMed Link to Article
Dixon  S McDonald  SRoberts  J The impact of HIV and AIDS on Africa's economic development. BMJ 2002;324 (7331) 232- 234
PubMed Link to Article
UNAIDS/World Health Organization, Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report.  Geneva, Switzerland UNAIDS/World Health Organization2009;
UNAIDS, Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support.  Geneva, Switzerland UNAIDS2007;
UNAIDS/World Health Organization, Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities.  Geneva, Switzerland UNAIDS/World Health Organization2007;
Stringer  JSZulu  ILevy  J  et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296 (7) 782- 793
PubMed Link to Article
Brinkhof  MPujades-Rodriguez  MEgger  M Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009;4 (6) e5790
PubMed Link to Article
Granich  RMGilks  CDye  CDe Cock  KWilliams  B Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373 (9657) 48- 57
PubMed Link to Article
 A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. HIV Prevention Trials Web site. http://www.hptn.org/research_studies/HPTN052.asp. Accessed June 12, 2009
Bassett  IVGiddy  JWang  B  et al.  Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med 2008;9 (10) 863- 867
PubMed
Bassett  IRegan  SChetty  S  et al.  Who starts ART in Durban, South Africa? not everyone who should [abstract WEAD102]. Conference of International AIDS Society July 19-22, 2009 Cape Town, South Africa
Rosen  SFox  MPGill  CJ Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4 (10) e298
PubMed Link to Article
 US Census Bureau International Data Base. US Census Bureau Web site. http://www.census.gov/ipc/www/idb/tables.html. Accessed July 15, 2009
Shisana  ORehle  TSimbayi  L  et al.  South African National HIV Prevalence, Incidence, Behaviour and Communication Survey: A Turning Tide Among Teenagers?  Cape Town, South Africa HSRC Press2008;
Parker  WMakhubele  BNtlabati  PConnolly  C Concurrent Sexual Partnerships Amongst Young Adults in South Africa: Challenges for HIV Prevention Communication.  Johannesburg, South Africa CADRE2007;
Williams  BGLloyd-Smith  JOGouws  E  et al.  The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med 2006;3 (7) e262
PubMed Link to Article
 World Health Organization life tables for WHO member states. World Health Organization Web site. http://www.who.int/whosis/database/life_tables/life_tables.cfm. Accessed July 15, 2009,
 Demographic and Health Survey, ORC Macro. http://www.measuredhs.com. Accessed May 1, 2010
Connolly  CSimbayi  LShanmugam  RNqeketo  A Male circumcision and its relationship to HIV infection in South Africa: results from a national survey in 2002. S Afr Med J 2009;98 (10) 789- 794
PubMed
Dorrington  RJohnson  LBradshaw  DDaniel  T The Demographic Impact of HIV/AIDS in South Africa: National and Provincial Indicators for 2006.  Cape Town, South Africa Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa2006;
Wawer  MJGray  RHSewankambo  NK  et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191 (9) 1403- 1409
PubMed Link to Article
Gray  RHWawer  MJBrookmeyer  R  et al. Rakai Project Team, Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357 (9263) 1149- 1153
PubMed Link to Article
Quinn  TCWawer  MJSewankambo  N  et al. Rakai Project Study Group, Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342 (13) 921- 929
PubMed Link to Article
Auvert  BTaljaard  DLagarde  ESobngwi-Tambekou  JSitta  RPuren  A Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2 (11) e298
PubMed Link to Article
Bailey  RCMoses  SParker  CB  et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369 (9562) 643- 656
PubMed Link to Article
Gray  RHKigozi  GSerwadda  D  et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369 (9562) 657- 666
PubMed Link to Article
Kamb  MLFishbein  MDouglas  JM  Jr  et al. Project RESPECT Study Group, Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280 (13) 1161- 1167
PubMed Link to Article
Williams  BGKorenromp  EGouws  ESchmid  GAuvert  BDye  C HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis 2006;194 (10) 1450- 1458
PubMed Link to Article
Auvert  BMales  SPuren  ATaljaard  DCaraël  MWilliams  B Can highly active antiretroviral therapy reduce the spread of HIV? a study in a township of South Africa. J Acquir Immune Defic Syndr 2004;36 (1) 613- 621
PubMed Link to Article
Badri  MLawn  SDWood  R Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008;889
PubMed Link to Article
Badri  MCleary  SMaartens  G  et al.  When to initiate highly active antiretroviral therapy in sub-Saharan Africa? a South African cost-effectiveness study. Antivir Ther 2006;11 (1) 63- 72
PubMed
Orrell  CHarling  GLawn  SD  et al.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007;12 (1) 83- 88
PubMed
Holmes  CBWood  RBadri  M  et al.  CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42 (4) 464- 469
PubMed Link to Article
Badri  MLawn  SDWood  R Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006;368 (9543) 1254- 1259
PubMed Link to Article
Lawn  SDLittle  FBekker  L  et al.  Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009;23 (3) 335- 342
PubMed Link to Article
Pettifor  AERees  HVKleinschmidt  I  et al.  Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005;19 (14) 1525- 1534
PubMed Link to Article
April  MWalensky  RChang  Y  et al.  Trends in HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies.  Conference on Retroviruses and Opportunistic Infections February 8-11, 2009 Montreal, Quebec, Canada
Bendavid  EYoung  SDKatzenstein  DABayoumi  AMSanders  GMOwens  DK Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a Southern African analysis. Arch Intern Med 2008;168 (17) 1910- 1918
PubMed Link to Article
Bendavid  EWood  RKatzenstein  DABayoumi  AMOwens  DK Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr 2009;52 (1) 106- 113
PubMed Link to Article
De Cock  KM Plenary talk.  HIV Implementers' Meeting June 10, 2009 Windhoek, Namibia
 2008 Report on the global AIDS epidemic: epidemiology information. Joint United Nations Programme on AIDS Web site. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed November 2008
 WHO Mortality Database. http://www.who.int/healthinfo/morttables/en/. Accessed June 29, 2009
Walensky  RWolf  LWood  R  et al.  When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151 (3) 157- 166
PubMed Link to Article
Vernazza  PHirschel  BBernasconi  EFlepp  M HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Bulletin des Médecins Suisses 2008;89 (5) 165- 169
Reynolds  SMakumbi  FKagaayi  J  et al.  ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda.  Presented at: Conference on Retroviruses and Opportunistic Infections February 8-11, 2009 Montreal, Quebec, Canada
Cassell  MMHalperin  DTShelton  JDStanton  D Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006;332 (7541) 605- 607
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com